Real-world study confirms the improved sensitivity of blue light vs white light cystoscopy (91% vs 79%) for detecting bladder cancer.
Study findings suggest that clinicians should use neoadjuvant chemotherapy in many more muscle-invasive bladder cancer patients.
The 5-year overall survival rate is significantly higher among radical cystectomy patients who receive neoadjuvant vs adjuvant chemotherapy, study finds.
Daily use of aspirin before radical cystectomy is associated with a significant 36% and 30% decreased risk of cancer-specific and all-cause mortality.
A study found that bladder cancer and UTUC occurred in 122.22 and 113.97 per 100,000 persons per year, respectively, among kidney transplant recipients.
Positive results before BCG treatment and at the 6-week instillation are associated with an increased likelihood of disease recurrence and/or progression.
Female sex and need for a blood transfusion are associated with development of Clostridium difficile infection following radical cystectomy.
Large study reveals a significant 15% survival advantage associated with radical cystectomy vs chemoradiation therapy.
Novel immunotherapies and chemotherapies hold promise as non-surgical salvage options.
Enhanced therapeutic effect of bacillus Calmette-Gurin tx in non-muscle invasive bladder cancer.
Men and women who smoke are at 2.3-fold and 2.7-fold increased risk of bladder cancer compared with non-smokers.
Instilling gemcitabine into the bladder immediately following resection of low-grade non-muscle-invasive bladder cancer significantly lowers recurrence risk.
One-year overall survival of 61% for gemcitabine and cisplatin plus ipilimumab.
When combined with cytology, UroSEEK detected 95% of patients who developed bladder cancer
Use of 5-alpha-reductase inhibitors before and after diagnosis of the malignancy is associated with a 15% and 22% decreased risk of bladder cancer mortality, respectively.
In multivariable analyses, CKD stage G3b or higher was significantly associated with worse progression-free and cancer-specific survival.
Model, based on 6 factors, predicts overall survival for patients treated with atezolizumab
Appears to be a cost-effective strategy for patients with small size, stage pTa or pT1a recurrent tumors
In a 3-year study, toxic effects of atezolizumab remained manageable and responses durable.
Study results serve as a caution against relying on ureteroscopic biopsy to establish tumor grade and stage, researchers say.
Patients with bladder adenocarcinomas have the best survival, whereas those with small cell carcinomas of the bladder have the worst.
In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.
Nicotine and nicotine-derived nitrosamine ketone enhance mutational susceptibility in human cells.
A Charlson Comorbidity Index score of 2 or higher is an independent risk factor for urinary tract infections within 90 days following radical cystectomy for bladder cancer, study finds.
Diffusion-weighted imaging and use of higher field strengths further improve accuracy.
The locoregional recurrence-free survival rate at 2 years was significantly higher for patients treated with chemotherapy plus RT versus those treated with chemotherapy alone.
Patients on hemodialysis who undergo radical cystectomy for bladder cancer have 30-day and 5-year mortality rates of 9.3% and 87.9%, respectively, study finds.
Patients with versus without a history of urinary calculi had nearly 2-fold greater odds of bladder cancer, meta-analysis showed.
40% of active surveillance events were deemed to require treatment.
Chemoradiation for muscle-invasive bladder cancer is associated with a lower 1-year mortality risk versus radical cystectomy, but at year 2 and beyond, mortality risk is lower with radical cystectomy.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)